AbbVie (ABBV) stock was one of the top gainers in the 澳洲幸运5官方开奖结果体彩网:S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to treat inflammation.

The company reported fourth-quarter revenue rose nearly 6% year-over-year to $15.1 billion, above the $14.8 billion consensus estimate of analysts surveyed by Visible Alpha. Adjusted 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) of $2.16 came in below forecasts.

Global sales of Skyrizi soared 58% to $3.78 billion, and rose 46% to $1.83 billion for Rinvoq. Those offset falling sales for Humira—once the world's top-selling drug—which has been losing market share because of generic competition. Humira sales slid 49% to $1.68 billion.

ꦓ AbbVie Sees Combined 2027 Skyrizi, Rinvoq Sales of More Than $31B

The company updated its long-term outlook for sales of Skyrizi and Rinvoq, anticipating combined sales of more than $31 billion in 2027. It had previously predicted more than $27 billion. It added that the guidanc𓆏e assumes revenues of more than $20 billion for Skyrizi and more than $11 billion for Rinvoq.

In addition, AbbVie sees aesthetics revenues through 2029 to be in♉ a h﷽igh-single-digit compound annual growth rate.

Shares of AbbVie, which surgedꩲ roughly 8% Friday, are🍎 up 15% over the last year.